- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04265703
The INVADE Study: INnominate Vein Approach for Central Catheterization in Difficult to cannulatE Patients (INVADE)
February 26, 2024 updated by: Miguel Á Ibarra-Estrada, Hospital Civil de Guadalajara
Central Venous Access in Patients With Difficult Cannulation, A Randomized Controlled Trial
Most recent guidelines suggest central venous access must be performed with real-time ultrasound guidance, and the most recommended site for cannulation is internal jugular vein (IJV); however, it is recognized that evidence for other sites is, at present, limited.
Besides, guidelines does not account for patients with small vein cross-sectional area and/or respirophasic collapse, which can make the procedure more difficult or even impossible.
The investigators aim to compare three different insertion sites for central venous access, with real-time ultrasound guidance
Study Overview
Status
Recruiting
Conditions
Detailed Description
Ultrasound-guided cannulation of central veins is successful in >95% of the cases, according to the largest study so far.
However, this and other studies with similar success rate, are performed in patients with general anesthesia and/or neuromuscular blockade, without spontaneous respiratory efforts.
Critical care physicians and many other specialists frequently need to cannulate patients in special circumstances as hypovolemia, pain, anxiety, and respiratory efforts that promotes respirophasic variation in cross-sectional area, and even complete collapse of the vessel.
These changes can increase the probability of posterior wall or arterial puncture, hematomas, pneumothorax, etc. Supraclavicular approach for cannulation of the subclavian vein is a method described since 1965, also giving direct access to the innominate vein, a larger vessel which is rarely collapsible regardless of volume status or respiratory efforts.
Based on a previous pilot trial, in this multi-center, prospective, randomized, controlled trial, the investigators aim to compare the successfulness and safety of ultrasound-guided central venous cannulation at 3 different sites: internal jugular, subclavian, and innominate veins.
Study Type
Interventional
Enrollment (Estimated)
300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Miguel Ibarra-Estrada, MD
- Phone Number: 3317593502
- Email: drmiguelibarra@hotmail.com
Study Contact Backup
- Name: Guadalupe Aguirre-Avalos, MD
Study Locations
-
-
-
Guadalajara, Mexico, 44280
- Recruiting
- Hospital Civil Fray Antonio Alcalde
-
Contact:
- Miguel Ibarra-Estrada, MD
- Phone Number: 3317593502
- Email: drmiguelibarra@hotmail.com
-
Contact:
- Guadalupe Aguirre-Avalos, MD
- Email: guadalupe.aavalos@academicos.udg.mx
-
Sub-Investigator:
- Quetzalcóatl Chávez-Peña, MD
-
Sub-Investigator:
- Arnulfo López-Pulgarín, MD
-
Principal Investigator:
- Miguel Ibarra-Estrada, MD
-
Sub-Investigator:
- Guadalupe Aguirre-Avalos, MD
-
Sub-Investigator:
- Pável Aguilera-González, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients who need central venous catheterization, and have respirophasic variation in cross-sectional area of jugular veins
Exclusion Criteria:
Less than 18 years-old
- Patients with previous failed attempts with non-ultrasound guided technique
- Non-resolved pneumothorax/hemothorax at enrollment
- Refusal to sign informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Internal jugular vein site
Ultrasound-guided central venous catheterization at internal jugular vein site
|
Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position.
Standard aseptic technique.
|
Active Comparator: Subclavian vein site
Ultrasound-guided central venous catheterization at subclavian vein site
|
Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction.
Standard aseptic technique.
|
Active Comparator: Innominate vein site
Ultrasound-guided central venous catheterization at innominate vein site
|
Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction.
Standard aseptic technique.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cannulation failure rate
Time Frame: Baseline
|
Failure to cannulate selected vein after three attempts
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collapsibility associated with failure
Time Frame: Baseline
|
Percentage of vein collapsibility independently associated with cannulation failure
|
Baseline
|
Cannulation number of attempts
Time Frame: Baseline
|
Number of attempts needed to attain cannulation
|
Baseline
|
Procedure time
Time Frame: Baseline
|
Time from skin puncture to guidewire confirmed into vessel (minutes)
|
Baseline
|
Arterial puncture rate
Time Frame: Baseline
|
Confirmed immediately after procedure with vascular ultrasound
|
Baseline
|
Hematoma formation rate
Time Frame: 7 days
|
Confirmed immediately after procedure with vascular ultrasound
|
7 days
|
Neumothorax rate
Time Frame: 7 days
|
Confirmed immediately after procedure with lung ultrasound
|
7 days
|
Hemothorax rate
Time Frame: 7 days
|
Confirmed immediately after procedure with lung ultrasound
|
7 days
|
Central line-associated blood infection rate
Time Frame: 28 days
|
Confirmed with blood cultures
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Miguel Ibarra-Estrada, MD, Hospital Civil Fray Antonio Alcalde
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 12, 2019
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
February 9, 2020
First Submitted That Met QC Criteria
February 9, 2020
First Posted (Actual)
February 11, 2020
Study Record Updates
Last Update Posted (Estimated)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 26, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCG/CEI-1196/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Illness
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedNeonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Yale UniversityNational Institute on Aging (NIA)RecruitingCritical Illness | Illness, CriticalUnited States
-
McMaster UniversityLondon Health Sciences Centre; McMaster Children's Hospital; Canadian Critical...CompletedPediatric Critical IllnessCanada
-
Boston Children's HospitalCompleted
-
St Helens & Knowsley Teaching Hospitals NHS TrustManchester University NHS Foundation TrustCompleted
-
Sándor BeniczkyUniversity of Aarhus; Danish Council for Independent Research; Søster og Verner...CompletedCritical Illness Myopathy | Myopathy Critical IllnessDenmark
-
Hospital de Clinicas de Porto AlegreUnknownCritical Illness PolyneuropathiesBrazil
-
Peking Union Medical College HospitalBaxter Healthcare CorporationUnknownNutrition Therapy for Critical Illness
-
Assistance Publique - Hôpitaux de ParisRecruitingCritical Illness Related Corticosteroids InsufficiencyFrance
-
Yuzuncu Yıl UniversityKahramanmaras Sutcu Imam University; Izmir Ataturk Training and Research HospitalCompleted
Clinical Trials on Internal jugular vein catheterization
-
Zonguldak Bulent Ecevit UniversityCompletedUltrasound | Catheterization | Volume StatusTurkey
-
Seoul National University HospitalNot yet recruiting
-
Seoul National University Bundang HospitalCompleted
-
Masarykova Nemocnice v Usti nad Labem, Krajska...CompletedCentral Vein CatheterCzechia
-
AC Camargo Cancer CenterCompletedCancer | Catheter ComplicationsBrazil
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedCOVID-19 PneumoniaTurkey
-
Ahmed Abd El-Rahim Abd El-Hamid HammadCompletedElectrical Cardiometry | Ultrasound of IJVEgypt
-
IRCCS Policlinico S. DonatoWithdrawnCongenital Heart Disease | Heart; Surgery, Heart, Functional Disturbance as Result | Central Venous Catheter Associated Bloodstream Infection | Newborn; Infection | Central Line-associated Bloodstream Infection (CLABSI)Italy
-
Samuel Lunenfeld Research Institute, Mount Sinai...Completed
-
Ankara UniversityCompletedComplication Rate | Number of TrialsTurkey